TABLE 1.
Patient characteristics.
| Characteristics | Total | No cancer or ciPCa | csPCa | p‐value |
|---|---|---|---|---|
| Patients, n (%) | 150 (100) | 85 (57) a | 65 (43) | ‐ |
| Age (year) |
65 (60–71) |
62 (59–68) |
68 (63–73) |
<0.001 |
| tPSA (ng/mL) |
5.8 (3.7–9.8) |
4.9 (3.1–7.8) |
7.5 (4.3–11.5) |
0.227 |
| Volume (mL) |
45.9 (34.8–64.9) |
50.1 (38.5–69.8) |
41.8 (29.0–56.6) |
0.003 |
| PSA density (ng/mL2) |
0.12 (0.08–0.20) |
0.10 (0.07–0.14) |
0.17 (0.12–0.29) |
<0.001 |
| Proclarix score |
30.8 (16.9–46.0) |
23.9 (14.7–36.7) |
40.4 (21.3–58.4) |
<0.001 |
| Proclarix density (%/mL) |
0.44 (0.25–0.71) |
0.90 (0.57–1.45) |
0.59 (0.31–1.03) |
<0.001 |
Note: Data presented in median and interquartile ranges (IQR).
Abbreviations: ciPCa, grade group < 2; csPCa, clinically significant prostate cancer (defined as grade group ≥ 2); tPSA, total prostate specific antigen.
a
63 (42%) pts no cancer, 22 (15%) pts ciPCa.